Sequencing of S and N genes of SARS-CoV-2 strains circulating in Cuba during March- September 2020

Abstract

ABSTRACT Objectives: The first confirmed cases of COVID-19 in Cuba were reported on March 11, 2020, followed by multiple introductions of infected travelers from Europe, America, and Asia. This work aimed to characterize the SARS-CoV-2 strains circulating in Cuba from March to September 2020 by partial nucleotide sequencing of the S and N genes. Methods: Between March and September 2020, 38 nasopharyngeal exudates from 38 SARS-CoV-2 patients were received at the National Reference Laboratory for Influenza and Respiratory Viruses at the Institute of Tropical Medicine “Pedro Kourí” (IPK). The Sanger sequencing method was used to amplify and sequence a 2539 bp fragment of the spike gene (from position 22020 to 24550) and a 370 bp of the nucleoprotein gene (from position 28340 to 28710). The GISAID database was used to identify the mutation profile of both fragments, and phylogenetic analysis was used to confirm the clades. In addition, clinical and epidemiological data from patients were gathered. Results: There were 34 and 25 sequences from S and N genes, respectively. In 21 of them, both genes (S and N) were available, whereas, in the remaining 13 and 4, only S or N sequences could be obtained. Based on the presence of the D614G mutation, 32 samples (84.2%) were classified as clade G of SARS CoV-2, and two were classified as Wuhan. No classification was possible in the remaining four (where only the N sequence was available). In one sample each, five different mutations were detected in clade G samples: L517F, L517X, N603T, A846V, and E281V. The 26 N sequences obtained were 100.0% identical to those circulated in most countries. The G30R mutation was detected in an infected patient in Cuba. Fourteen of the 38 patients studied were imported cases. The first three cases detected with COVID-19 in Cuba were clade G and originated in Italy. Ten individuals were asymptomatic, four presented severe forms of the disease (two fatal), and the remaining presented mild symptoms. No relationship was observed among the clades or the mutational profile with the clinical features, country of origin, and Cuban provinces. Conclusion: The early establishment of SARS-CoV-2 genetic surveillance in Cuba was helpful for tracking the epidemic. It demonstrated that the SARS-CoV-2 clade G was introduced initially and was the variant that circulated in the country during 2020, although the Wuhan strain was also detected. J Microbiol Infect Dis 2022; 12(3):77-88.

Keywords

• sequencing
• S gene
• N gene
• SARS-CoV-2
• Cuba

Kaynakça

1. 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine 2020; 382:727-733.
2. 2. WHO. Coronavirus Disease (COVID-19) Situation Reports 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 3. Beldarraín E, Alfonso I, Morales I, Durán F. Primer acercamiento histórico-epidemiológico a la COVID-19 en Cuba. Ciencias Biomedicas 2020; 10(2).
3. 4. Portal Miranda J. Hitos y alcance de la respuesta cubana a la COVID-19. Boletín de la Cooperación Técnica Cuba 2021; 25(1):4-11.
4. 5. Portal Miranda J. Intervención sanitaria con candidatos vacunales, como estrategia temporal de enfrentamiento a la COVID-19. Revista Cubana de Salud Pública 2021; 48(1): e3513.
5. 6. Hu B, Guo H. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology 2021; 19:141-154.
6. 7. McNamara RP, Caro-Vegas C, Landis JT, et al. High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States. Cell Rep 2020; 33(5):108352.
7. 8. Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ 2020; 98:495-504.
8. 9. Rambaut A, Holmes EC, O’TooleÁ, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Natur Microbiol 2020; 5(11): 1403–1407.

9. 10. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 2020; 182: 812-827 e819.
10. 11. Hamed SM, Elkhatib W, Khairalla A, Noreddin A. Global dynamics of SARS‑CoV‑2 clades and their relation to COVID‑19 epidemiology. Scientific Report 2021; 11:8435
11. 12. GISAID: CoVsurver: Mutation Analysis of hCoV-19. 2020. [cited 2020 November 20]. Available from: https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/.
12. 13. PAHO: Guidance for SARS-CoV-2 samples selection for genomic characterization and surveillance 2021. Available from: https://www.paho.org/en/documents/guidance-sars-cov-2-samples-selection-genomic-characterization-and-surveillance
13. 14. Centers for Diseases Control and Prevention. Protocols for SARS-CoV-2 sequencing. 2020. Available from: https://github.com/CDCgov/SARS-CoV-2_Sequencing.
14. 15. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0. Molecular Biology and Evolution 2013; 30:2725-2729.
15. 16. Rahimi A, Mirzazadeh A, Tavakolpour S. Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics 2021; 113(1): 1221-1232.
16. 17. Long SW, Olsen RJ, Christensen PA, et al. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. mBio 2020; 11(6).
17. 18. OPS/OMS: Caracterización genómica del SARS-CoV-2 y variantes circulantes en la Región de las Américas. Organización Panamericana de la Salud 2020. Available from: https://www.geuvih.org/wp-content/uploads/2020/10/Caracterizaci%C3%B3n-gen%C3%A9tica-del-SARS-CoV-2-en-las-Am%C3%A9ricas.pdf
18. 19. Chen Z, Chong KC, Wong MCS, et al. A global analysis of replacement of genetic variants of SARS-CoV-2 in association with containment capacity and changes in disease severity. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2021; 27:750-757.
19. 20. Laha S, Chakraborty J, Das S, Manna SK, Biswas S, Chatterjee R. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect Genet Evol 2020; 85:104445.
20. 21. Zhang L, Jackson CB, Mou H, et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. Nat Comun 2020; 11:6013.
21. 22. Renn M, Bartok E, Zillinger T, Hartmann G, Behrendte R. Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. Pharmacol Ther 2021; 228:107931.
22. 23. WHO: WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern, 2021. Available from: https://www.who.int/news/item/31-05-2021
23. 24. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19) 2020; [cited 2020 December 28]. Available from: OurWorldInData.org.
24. 25. Sengupta A, Hassan S, Choudhuryc PP. Clade GR and clade GH isolates of SARS-CoV-2 in Asia show highest amount of SNPs. Infect Genet Evol 2021; 89:104724.
25. 26. Chen J, Gao K, Wang R, Wei G: Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. Chem Sci 2021; 12: 6929-6948.
26. 27. CubaData [Internet]. 2020 [cited 2020 November 29]. Available from: https://covid19cubadata.github.io/#cuba.
27. 28. PAHO: Cuba frente a la Covid-19. Boletin de la OPS/OMS en Cuba 2020; 2 (204).